Earningsreport

Q2/2024 6/30/2024 EPS -0.590 ZacksConsensus -0.830 ActVsEst 0.240 - Beat

Relmada Therapeutics, Inc.  (RLMD) 
NASDAQ:AMEX Investor Relations: ir.relmada.com